Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15881734 | 0.90 | KMT2A (0.49) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL26481653 | 0.85 | NPC1 (0.51) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL27504825 | 0.84 | KMT2A (0.44) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL15616516 | 0.82 | KMT2A (0.55) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL527357 | 0.80 | KMT2A (0.49) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL18952480 | 0.80 | S1PR4 (0.56) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL8568195 | 0.79 | KMT2A (0.36) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL8789338 | 0.79 | KMT2A (0.54) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL8437 | 0.79 | HTT (0.55) | KMT2AMEN1NPC1S1PR4RAB9A | |
| SCHEMBL8159969 | 0.79 | KMT2A (0.54) | KMT2AMEN1NPC1S1PR4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2991978-B1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F HOFFMANN LA ROCHE SA (CH) | 2025-08-20 | — | — | EP | disclosed |
| CN-110003178-B | Diheteroaryl compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3083599-B1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | HOFFMANN LA ROCHE (CH) | 2020-07-01 | — | — | EP | disclosed |
| EP-3083599-B1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | HOFFMANN LA ROCHE (CH) | 2020-07-01 | — | — | EP | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| CN-105939997-B | Pyrazole derivatives as DLK inhibitors and uses thereof | 豪夫迈·罗氏有限公司 | 2020-01-21 | — | — | CN | disclosed |
| CN-105431420-B | Diheteroaryl compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2019-08-13 | — | — | CN | disclosed |
| WO-2015091889-A1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015091889-A1 | PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175619-A1 | SUBSTITUTED PYRAZOLES AND USES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2014177060-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014177060-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014111496-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014111496-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| EP-0735025-B1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL CO (JP) | 1998-07-01 | — | — | EP | disclosed |
| US-5648496-A | AMINATION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-15 | — | — | US | disclosed |
| EP-0735025-A1 | Process for producing aminonitropyridines | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | KMT2A 2566/4885MEN1 677/4885NPC1 1986/4885 |
| US-20150175619-A1 | SUBSTITUTED PYRAZOLES AND USES THEREOF | PDXK, NLK, PDK3 | KMT2A 1979/4885MEN1 2337/4885NPC1 3357/4885 |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | KMT2A 2566/4885MEN1 677/4885NPC1 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.